Clinical Trials Directory

We are doing this study to find out if an experimental drug called ruxolitinib is a safe and effection option for preventing graft-versus-host disease when it is given in combination with the drugs tacrolimus and methotrexate before and after a peripheral blood stem cell transplant. We want to know if this study drug combination works better than the standard post-transplant treatment of cyclophosphamide, tacrolimus, and mycophenolate mofetil.

We are doing this study to find out if patients with SAA who have not received previous treatment for this diagnosis can be treated safely and effectively with transplant as their first therapy.

We are doing this study to see if a pair of experimental drugs called botensilimab and balstilimab are safe and effective options for colorectal cancer.

We created this healthy volunteer registry for people who would like to participate in brain imaging research studies. These studies use structural and functional MRI data to study areas of the brain associated with movement, memory, attention, and perception.

We are doing this study to better understand women's preferences for and concerns about hormone replacement. We want to learn from women who have had their fallopian tubes and ovaries removed due to BRCA1 and BRCA2 mutations.

We are doing this study to try and find a way to detect breast cancer earlier or before it recurs.

We are doing this study to find out if an experimental drug called zifibancimig (the study drug) is a safe and effective option for people with neovascular age-related macular degeneration (nAMD). We want to see how well it works in comparison to ranibizumab, which is an FDA-approved drug for the treatment of nAMD. Both the study drug and approved drug that are used in this study are given as eye implants.

We are doing this study to determine if long-term treatment with camizestrant after surgery is a safe and effective option for treating patients with early-stage ER+/HER2- breast cancer. We want to compare the outcomes of using camizestrant to current standard of care treatments (endocrine therapy).